This regulatory milestone follows Solventum’s acquisition of Acera Surgical last December, a strategic move designed to consolidate their portfolio of wound management solutions. By pairing the two systems, clinicians can now utilize the Restrata Matrix to provide necessary scaffolding for soft tissue repair while simultaneously employing V.A.C. Therapy to foster an environment conducive to tissue integration. The combined approach aims to streamline complex wound care procedures by leveraging the unique mechanical properties of the synthetic fiber matrix alongside the established benefits of negative pressure wound therapy.